{"id":"W4412620438","doi":"10.1182/bloodadvances.2024015014","title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Pharmacyclics; Eurostars; Genentech; Health Resources and Services Administration; Aptitude Health; Seagen; Incyte; Juno Therapeutics; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Gateway for Cancer Research; Celgene; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Alexion Pharmaceuticals; Spectrum Pharmaceuticals; Mallinckrodt Pharmaceuticals; Kite Pharma; Society for Immunotherapy of Cancer; Astellas Pharma US; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Bendamustine; Mantle cell lymphoma; Cumulative incidence; Oncology; Confidence interval; Salvage therapy; Odds ratio; Melphalan; Gastroenterology; Lymphoma; Surgery; Transplantation; Chemotherapy; Rituximab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004081823,0.0003595522,0.0005876281,0.001030291,0.0002365669,0.001273918,0.0005049353,0.0004518911,0.001557503],"category_scores_gemma":[0.004249487,0.0001929488,0.001549316,0.001120374,0.0003692024,0.0007569981,0.0008381612,0.0005987444,0.0003304865],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008366004,"about_ca_system_score_gemma":0.0003839645,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007755329,"about_ca_topic_score_gemma":0.0008563636,"domain_scores_codex":[0.9976967,0.001027943,0.0002889024,0.0003749619,0.0003879584,0.0002234799],"domain_scores_gemma":[0.993372,0.001744263,0.003294151,0.0004902016,0.0005567405,0.0005426772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007857267,0.0002801627,0.9794903,0.0001402369,0.001670491,0.0001766715,0.00009207234,0.001425802,0.0004520413,0.00006931822,0.0004501492,0.007895414],"study_design_scores_gemma":[0.0004115016,0.003441284,0.9906237,0.000033688,0.001044292,0.0006687429,0.0001698162,0.002016514,0.000505257,0.00006289356,0.0009885613,0.00003386],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971738,0.0006387683,0.0002441102,0.00003484185,0.000004773445,0.00003379805,0.00145576,0.000005791551,0.0004083653],"genre_scores_gemma":[0.9971145,0.0001140091,0.00008813915,0.00002600939,0.00001077089,0.00002898311,0.002527892,0.00000333904,0.00008632244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004081823,"threshold_uncertainty_score":0.02158701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02176219910519934,"score_gpt":0.3536270628012587,"score_spread":0.3318648636960594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}